Do you offer bevacizumab to patients more than 65 years old with metastatic colon cancer that are KRAS mutant?

Great question. I think the data would argue that on a case-by-case basis you can give bevacizumab safely. Metaanalyses suggest that PFS and OS are improved in a statistically significant way with the addition of bev (PFS HR 0.55, OS HR 0.83), but so are AE's (Fistula OR 12.07!!, Arterial embolism O...